tbuckley/cabot-search huggingface dataset:
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial
Journal: The Lancet (2019)

Tranexamic acid reduces surgical bleeding and decreases mortality in patients with traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury (TBI) and can cause brain herniation and death. We aimed to assess the effects of tranexamic acid in patients with TBI.
Books in Brief
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Should Prophylactic Transanal Tube Drainage Be Continued in Colorectal Surgery?—Reply
Authors: Song Zhao, Li Wang, Weidong Tong
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Overcoming Our Red Dots and Confronting Racism From Patients
Authors: Udit Singhal
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Extracellular Vesicle–Packaged CDH11 and ITGA5 Induce the Premetastatic Niche for Bone Colonization of Breast Cancer Cells
Authors: Xiao-Qing Li, Rui Zhang, Hong Lu, Xiao-Min Yue, Yu-Fan Huang
Journal: Cancer Research (2022)

Although most breast cancer metastases in bone cause osteolytic lesions, the osteogenic niche has commonly been described as an initiator of early-stage bone colonization of disseminated cancer cells. Tumor cell-derived extracellular vesicles (EV) have been shown to determine the organotropism of cancer cells by transferring their cargo, such as nucleic acids and proteins, to resident cells at future metastatic sites and preparing a favorable premetastatic niche. Runt-related transcription factor 2 (RUNX2) and its regulated genes have been shown to facilitate the acquisition of osteomimetic features and to enhance the bone metastatic potential of breast cancer cells. In this study, we present in vivo and in vitro evidence to clarify the role of EVs released by breast cancer cells with high RUNX2 expression in the education of osteoblasts to form an osteogenic premetastatic niche. Furthermore, different extracellular vesicular proteins were identified that mediate events subsequent to the specific recognition of tumor-derived EVs by osteoblasts via cadherin 11 (CDH11) and the induction of the osteogenic premetastatic niche by integrin α5 (ITGA5). CDH11high/ITGA5high EVs were demonstrated to be responsible for the formation of a premetastatic niche that facilitates RUNX2 high-expressing breast cancer cell colonization in bone, revealing a potential EV-based premetastatic niche blockage strategy.This study provides mechanistic insights into the generation of an osteogenic premetastatic niche by breast cancer-derived EVs and identifies potential EV-derived diagnostic biomarkers and targets for breast cancer bone metastasis.
Current Licensure Requirements
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epidemic Influenza; Notes on its Origin and Method of Spread.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Authors: George Goshua, Pranay Sinha, Natalia Kunst, Lauren Pischel, Alfred Ian Lee, Adam Cuker
Journal: American Journal of Hematology (2022)

Major options for second-line therapy in adults with chronic immune thrombocytopenia (ITP) include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The American Society of Hematology guidelines recommend rituximab over splenectomy, TRAs over rituximab, and splenectomy or TRAs while noting a lack of evidence on the cost-effectiveness of these therapies. Using prospective, observational, and meta-analytic data, we performed the first cost-effectiveness analysis of second-line therapies in chronic ITP, from the perspective of the U.S. health system. Over a 20-year time-horizon, our six-strategy Markov model shows that a strategy incorporating early splenectomy, an approach at odds with current guidelines and clinical practice, is the cost-effective strategy. All four strategies utilizing TRAs in the first or second position cost over $1 million per quality-adjusted life-year, as compared to strategies involving early use of splenectomy and rituximab. In a probabilistic sensitivity analysis, early use of splenectomy and rituximab in either order was favored in 100% of 10 000 iterations. The annual cost of TRAs would have to decrease over 80% to begin to become cost-effective in any early TRA strategy. Our data indicate that effectiveness of early TRA and late TRA strategies is similar with the cost significantly greater with early TRA strategies. Contrary to current practice trends and guidelines, early use of splenectomy and rituximab, rather than TRAs, constitutes cost-effective treatment in adults with chronic ITP.
Obituaries
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impaired p47phox phosphorylation in neutrophils from patients with p67phox-deficient chronic granulomatous disease
Authors: Sahra Amel Belambri, Viviana Marzaioli, Margarita Hurtado-Nedelec, Coralie Pintard, Shiyu Liang, Yezhou Liu, Tarek Boussetta, Marie-Anne Gougerot-Pocidalo, Richard D. Ye, Pham My-Chan Dang, Jamel El-Benna
Journal: Blood (2022)
Errata in first list
Authors: V Steele, Mark Jackson
Journal: BMJ (1892)

SIR,-We beg to forward herewith a second list of subscrip- tions to the " Steele v. Savory Fund," which includes several amounts previously omitted.We desire to explain, in answer to inquiries, that the subscriptions now being acknowledged are those only which have been sent to the Treasurer of the Special Committee appointed in February last after the ter- mination of the action.A "1Guarantee Fund " was esta- blished on the commencement of the proceedings three years ago, towards which about £250 was received (some further contributions to this fund, promised but not then paid, have since been sent to the Special Committee and included in their first list).This amount was all expended during the progress of the action, but is allowed for in thle bill of costs now delivered, from which it will be deducted.It will be seen that there is still a balance of about £P1,000 required, which would be easily obtained if every Member who hat hitherto taken an interest in College reform were to send a few shillinigs.We should like to take this opportunity of reminding our numerous Local Secretaries of the letter which we recently sent
Access denied
Authors: Dan Lloyd
Journal: Behavioral and Brain Sciences (1995)

Abstract The information processing that constitutes accessconsciousness is not sufficient to make a representational state conscious in any sense. Standard examples of computation without consciousness undermine A-consciousness, and Block's cases seem to derive their plausibility from a lurking phenomenal awareness. That is, people and other minded systems seem to have access-consciousness only insofar as the state accessed is a phenomenal one, or the state resulting from access is phenomenal, or both.
Nuclear War
Authors: M. Barber, V. A. Kumoji, E. G. L. Bywaters, D. Lilaram, I. Datt, G. McCarthy, N. Datta, C. Pallis, J. Daly, J. Payne, A. Dixon, M. Segall, R. Haslam, D. R. Smith, T. Hazra, C. Vas, R. Hollister, L. Verma, D. Hull, I. Wooton, M. Kochhar
Journal: BMJ (1961)
Acute exacerbations in children’s interstitial lung disease
Authors: Elias Seidl, Nicolaus Schwerk, Julia Carlens, Martin Wetzke, Nagehan Emiralioğlu, Nural Kiper, Joanna Lange, Katarzyna Krenke, Zsolt Szepfalusi, Florian Stehling, Winfried Baden, Susanne Hämmerling, Silvija-Pera Jerkic, Marijke Proesmans, Nicola Ullmann, Frederik Buchvald, Katrin Knoflach, Matthias Kappler, Matthias Griese
Journal: Thorax (2022)

Introduction Acute exacerbations (AEs) increase morbidity and mortality of patients with chronic pulmonary diseases. Little is known about the characteristics and impact of AEs on children's interstitial lung disease (chILD). Methods The Kids Lung Register collected data on AEs, the clinical course and quality of life (patient-reported outcomes - PRO) of rare paediatric lung diseases. Characteristics of AEs were obtained. Results Data of 2822 AEs and 2887 register visits of 719 patients with chILD were recorded. AEs were characterised by increased levels of dyspnoea (74.1%), increased respiratory rate (58.6%) and increased oxygen demand (57.4%). Mostly, infections (94.4%) were suspected causing an AE. AEs between two register visits revealed a decline in predicted FEV1 (median −1.6%, IQR −8.0 to 3.9; p=0.001), predicted FVC (median −1.8%, IQR −7.5 to 3.9; p=0.004), chILD-specific questionnaire (median −1.3%, IQR −3.6 to 4.5; p=0.034) and the physical health summary score (median −3.1%, IQR −15.6 to 4.3; p=0.005) compared with no AEs in between visits. During the median observational period of 2.5 years (IQR 1.2–4.6), 81 patients died. For 49 of these patients (60.5%), mortality was associated with an AE. Conclusion This is the first comprehensive study analysing the characteristics and impact on the clinical course of AEs in chILD. AEs have a significant and deleterious effect on the clinical course and health-related quality of life in chILD.
Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance
Authors: Tianqi Liu, Chen Zhu, Xin Chen, Gefei Guan, Cunyi Zou, Shuai Shen, Jianqi Wu, Yuhang Wang, Zhiguo Lin, Ling Chen, Peng Cheng, Wen Cheng, Anhua Wu
Journal: Neuro-Oncology (2022)

Abstract Background Immunosuppressive microenvironment is a major cause of immunotherapeutic resistance in glioma. In addition to secreting compounds, tumor cells under programmed cell death (PCD) processes release abundant mediators to modify the neighboring microenvironment. However, the complex relationship among PCD status, immunosuppressive microenvironment, and immunotherapy is still poorly understood. Methods Four independent glioma cohorts comprising 1,750 patients were enrolled for analysis. The relationships among PCD status, microenvironment cellular components, and biological phenotypes were fully explored. Tissues from our hospital and experiments in vitro and in vivo were used to confirm the role of ferroptosis in glioma. Results Analyses to determine enriched PCD processes showed that ferroptosis was the main type of PCD in glioma. Enriched ferroptosis correlated with progressive malignancy, poor outcomes, and aggravated immunosuppression in glioblastoma (GBM) patients. Enhanced ferroptosis was shown to induce activation and infiltration of immune cells but attenuated antitumor cytotoxic killing. Tumor-associated macrophages (TAMs) were found to participate in ferroptosis-mediated immunosuppression. Preclinically, ferroptosis inhibition combined with Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand-1 (PD-L1) blockade generated a synergistic therapeutic outcome in GBM murine models. Conclusions This work provides a molecular, clinical, and biological landscape of ferroptosis, suggesting a role of ferroptosis in glioma malignancy and a novel synergic immunotherapeutic strategy that combines immune checkpoint blockade treatment with ferroptosis inhibition.
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
Authors: Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C. Caron, Lorenzo Falchi, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Erel Joffe, Niloufer Khan, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Lia M. Palomba, Ildefonso Rodriguez-Rivera, David Straus, Gottfried von Keudell, Andrew D. Zelenetz, Joachim Yahalom, Ahmet Dogan, Heiko Schöder, Venkatraman E. Seshan, Gilles Salles, Anas Younes, Connie L. Batlevi
Journal: Blood Cancer Journal (2022)

Abstract Between 1998 and 2009, a total of 295 patients (median age 58, 53% females) with newly diagnosed early-stage follicular lymphoma (FL) were managed at Memorial Sloan Kettering Cancer Center. Approximately half of patients (137, 46%) underwent initial observation and half (158, 54%) immediate treatment: radiation alone ( n = 108), systemic treatment alone ( n = 29), or combined modality treatment ( n = 21). Median follow-up was 8.4 years (range 0.3–17.2), and 10-year overall survival (OS) was 87.2%. OS was similar between initially-observed and immediately-treated patients (hazard ratio [HR]: 1.25, 95% CI: 0.67–2.36, p = 0.49). For patients receiving radiation alone, 5-year OS was 98.0%. Patients selected for systemic therapy alone had high-risk baseline features and had shorter OS than patients treated with radiation alone (HR 3.38, 95% CI 1.29–8.86, p = 0.01). Combined modality treatment did not yield superior survival compared with radiation alone ( P &gt; 0.05) but was associated with better progression-free survival (HR 0.36, 95% CI 0.14–0.90, p = 0.03). The rate of transformation increased steadily over time and was 4.2% at 5 years and 10.8% at 10 years. This modern-era analysis rationalized the role of initial observation in patients with early-stage FL although patients receiving radiation therapy also demonstrate excellent outcome.
Dilated cardiomyopathy
Authors: Heinz-Peter Schultheiss, DeLisa Fairweather, Alida L. P. Caforio, Felicitas Escher, Ray E. Hershberger, Steven E. Lipshultz, Peter P. Liu, Akira Matsumori, Andrea Mazzanti, John McMurray, Silvia G. Priori
Journal: Nature Reviews Disease Primers (2019)
Yoicks
Authors: John B. Pfeiffer
Journal: JAMA (1963)

<h3>To the Editor:</h3> —I read with interest the article by Ashley Montagu in the Sept 28, 1963, issue ofThe Journal(<b>185</b>:1017). After noting his characterization of the previously suggested methods of development of human speech, I could not resist suggesting that perhaps Dr. Montagu's theory be characterized as the<i>yoicks or tallyho</i>theory.
Part 7: Neonatal Resuscitation
Journal: Circulation (2005)

A pproximately 10% of newborns require some assistance to begin breathing at birth, and about 1% require extensive resuscitation.Although the vast majority of newborn infants do not require intervention to make the transition from intrauterine to extrauterine life, the large number of births worldwide means that many infants require some resuscitation.Newborn infants who are born at term, had clear amniotic fluid, and are breathing or crying and have good tone must be dried and kept warm but do not require resuscitation.All others need to be assessed for the need to receive one or more of the following actions in sequence:A. Initial steps in stabilization (clearing the airway, positioning, stimulating) B. Ventilation C. Chest compressions D. Medications or volume expansion Progression to the next step is based on simultaneous assessment of 3 vital signs: respirations, heart rate, and color.Progression occurs only after successful completion of the preceding step.Approximately 30 seconds is allotted to complete one step successfully, reevaluate, and decide whether to progress to the next (Figure).Since publication of the last International Liaison Committee on Resuscitation (ILCOR) document, 1 several controversial neonatal resuscitation issues have been identified.The literature was researched and a consensus was reached on the role of supplementary oxygen, peripartum management of meconium, ventilation strategies, devices to confirm placement of an advanced airway (eg, tracheal tube or laryngeal mask airway [LMA]), medications, maintenance of body temperature, postresuscitation management, and considerations for withholding and discontinuing resuscitation.
PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity
Authors: Daisuke Sugiura, Il-mi Okazaki, Takeo K. Maeda, Takumi Maruhashi, Kenji Shimizu, Rieko Arakaki, Tatsuya Takemoto, Naozumi Ishimaru, Taku Okazaki
Journal: Nature Immunology (2022)